Enzyme:CYP2C19: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) m MDElliottMD moved page Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2C19 to Enzyme:CYP2C19: Migrate enzyme entity pages from Pharmacogenomics sandbox to the new Enzyme: namespace |
MDElliottMD (talk | contribs) Add scope="col" to the data-table column headers for screen-reader association (ADA audit M5; designer-claude 2026-05-22) |
||
| Line 8: | Line 8: | ||
{| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;" | {| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;" | ||
|+ style="white-space:nowrap; text-align:left;" | near-complete CYP2C19 substrate table (click to expand) | |+ style="white-space:nowrap; text-align:left;" | near-complete CYP2C19 substrate table (click to expand) | ||
! Substrate !! Therapeutic class !! CYP2C19 contribution !! Clinical notes | ! scope="col" | Substrate !! scope="col" | Therapeutic class !! scope="col" | CYP2C19 contribution !! scope="col" | Clinical notes | ||
|- | |- | ||
| [[Amitriptyline]] || Tricyclic antidepressant || partial || N-demethylation to nortriptyline is partly CYP2C19; CYP2D6 dominates the hydroxylation step. | | [[Amitriptyline]] || Tricyclic antidepressant || partial || N-demethylation to nortriptyline is partly CYP2C19; CYP2D6 dominates the hydroxylation step. | ||
| Line 71: | Line 71: | ||
{| class="wikitable" | {| class="wikitable" | ||
! Phenotype !! Abbreviation !! Diplotype (typical) !! Approximate frequency | ! scope="col" | Phenotype !! scope="col" | Abbreviation !! scope="col" | Diplotype (typical) !! scope="col" | Approximate frequency | ||
|- | |- | ||
| [[Phenotype:CYP2C19 poor metabolizer|Poor metabolizer]] || PM || two no-function alleles || 2–5% European, 13–23% East Asian, 4% African | | [[Phenotype:CYP2C19 poor metabolizer|Poor metabolizer]] || PM || two no-function alleles || 2–5% European, 13–23% East Asian, 4% African | ||